MNPR compared with IVVD: revenue, margins and what each company keeps, and the suppliers and customers both name

MNPRMonopar Therapeutics

Mkt capRevenueRevenue

IVVDInvivyd, Inc.

Mkt capRevenueRevenue

Compare

MNPRMonopar Therapeutics

IVVDInvivyd, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

MNPR: latest quarter not drawable. IVVD: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only MNPR 2

AZNAstraZenecasupplier

—NorthStarunlistedsupplier

Shared 0

No shared counterparties.

Only IVVD 9

—Undisclosed specialty distributor customerunlistedcustomer

—Adimabunlistedsupplier

—WuXi Biologicsunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—WuXi Biologics (Hong Kong)unlistedsupplier

5 more · IVVD chain ›

Price

rebased to 0%

MNPR, solidIVVD, dashed

MNPRMonopar Therapeutics

71.60▲+2.45%· post 71.59

Mkt cap$469.1MRevenue—Revenue—

IVVDInvivyd, Inc.

0.64▲+9.41%· post 0.66

ClosedNov 4 '26

Mkt cap$186.8MRevenue$14MQ2 FY26Revenue$53MFY25

Compare

ClosedNov 4 '26

MNPRMonopar Therapeutics

IVVDInvivyd, Inc.

71.60▲+2.45%post 71.59

Price

0.64▲+9.41%post 0.66

$469.1M

Mkt cap

$186.8M

—

Revenue

$14MQ2 FY26

—

Revenue

$53MFY25

MNPR71.60▲+2.45%vsIVVD0.64▲+9.41%ClosedNov 4 '26